Radiosensitivity, Radiogenomics and RAPPER

Clinical Oncology

Volumn 18, Issue 7, 2006, Pages 525-528

  Burnet, N G ^a   Elliott, R M ^b   Dunning, A ^c   West, C M L ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1;

ALLELE; CANCER CONTROL; CANCER RADIOTHERAPY; DISEASE SEVERITY; DNA DAMAGE; EDITORIAL; GENE FREQUENCY; GENE MUTATION; GENETIC PREDISPOSITION; GENOMICS; GENOTYPE; HIGH RISK PATIENT; HIGH THROUGHPUT SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SICKNESS; RADIOSENSITIVITY; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT PLANNING;

GENOME, HUMAN; GENOMICS; HUMANS; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; RADIATION TOLERANCE;

EID: 33746480324     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.05.007     Document Type: Editorial

References (39)

1. Benson R.J., and Burnet N.G. Altered radiotherapy fractionation: an opportunity not to be missed. Clin Oncol (R Coll Radiol) 10 (1998) 150-154
2. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44 (1997) 111-121
3. Saunders M., Dische S., Barrett A., Harvey A., Gibson D., and Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 350 (1997) 161-165
4. Brenner D.J. Hypofractionation for prostate cancer radiotherapy-what are the issues?. Int J Radiat Oncol Biol Phys 57 (2003) 912-914
5. Logue J.P., Cowan R.A., and Hendry J.H. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys 49 (2001) 1522-1523
6. Holthusen H. Erfahrungen über die Verträglichkeitsgrenze für Röntgenstrahlen and deren Nutzanwendung zur Verhütung von Schäden. Strahlentherapie 57 (1936) 254-269
7. Turesson I. Individual variation and dose dependency in the progression rate of skin telangiectasia. Int J Radiat Oncol Biol Phys 19 (1990) 1569-1574
8. Turesson I. Characteristics of dose-response relationships for late radiation effects: an analysis of skin telangiectasia and of head and neck morbidity. Radiother Oncol 20 (1991) 149-158
9. Turesson I., and Notter G. Skin reactions after different fractionation schedules giving the same cumulative radiation effect. Acta Radiol Ther Phys Biol 14 (1975) 475-484
10. Turesson I., Nyman J., Holmberg E., and Oden A. Prognostic factors for acute and late skin reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys 36 (1996) 1065-1075
11. Turesson I., and Thames H.D. Repair capacity and kinetics of human skin during fractionated radiotherapy: erythema, desquamation, and telangiectasia after 3 and 5 years' follow-up. Radiother Oncol 15 (1989) 169-188
12. Bentzen S.M., and Overgaard M. Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. Radiother Oncol 20 (1991) 159-165
13. Russell N.S., Knaken H., Bruinvis I.A., Hart A.A., Begg A.C., and Lebesque J.V. Quantification of patient to patient variation of skin erythema developing as a response to radiotherapy. Radiother Oncol 30 (1994) 213-221
14. Burnet N.G., Johansen J., Turesson I., Nyman J., and Peacock J.H. Describing patients' normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy. Int J Cancer 79 (1998) 606-613
15. Burnet N.G., Wurm R., Nyman J., and Peacock J.H. Normal tissue radiosensitivity-how important is it?. Clin Oncol (R Coll Radiol) 8 (1996) 25-34
16. MacKay R.I., Niemierko A., Goitein M., and Hendry J.H. Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiother Oncol 46 (1998) 215-216
17. Roberts S.A., Spreadborough A.R., Bulman B., Barber J.B., Evans D.G., and Scott D. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer?. Am J Hum Genet 65 (1999) 784-794
18. Brock W.A., Tucker S.L., Geara F.B., et al. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 32 (1995) 1371-1379
19. Burnet N.G., Nyman J., Turesson I., Wurm R., Yarnold J.R., and Peacock J.H. Prediction of normal-tissue tolerance to radiotherapy from in-vitro cellular radiation sensitivity. Lancet 339 (1992) 1570-1571
20. Johansen J., Bentzen S.M., Overgaard J., and Overgaard M. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiother Oncol 40 (1996) 101-109
21. Peacock J., Ashton A., Bliss J., et al. Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother Oncol 55 (2000) 173-178
22. Dikomey E., Borgmann K., Peacock J., and Jung H. Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. Int J Radiat Oncol Biol Phys 56 (2003) 1194-1200
23. West C.M., Davidson S.E., Elyan S.A., et al. Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 51 (2001) 10-15
24. Dickson J., Magee B., Stewart A., and West C.M. Relationship between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiation reactions: a comparison of training and validation cohorts of breast cancer patients. Radiother Oncol 62 (2002) 321-326
25. Kiltie A.E., Orton C.J., Ryan A.J., et al. A correlation between residual DNA double-strand breaks and clonogenic measurements of radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. Int J Radiat Oncol Biol Phys 39 (1997) 1137-1144
26. Hoeller U., Borgmann K., Bonacker M., et al. Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. Radiother Oncol 69 (2003) 137-144
27. Barber J.B., West C.M., Kiltie A.E., Roberts S.A., and Scott D. Detection of individual differences in radiation-induced apoptosis of peripheral blood lymphocytes in normal individuals, ataxia telangiectasia homozygotes and heterozygotes, and breast cancer patients after radiotherapy. Radiat Res 153 (2000) 570-578
28. Carlomagno F., Burnet N.G., Turesson I., et al. Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities. Int J Cancer 85 (2000) 845-849
29. Bremer M., Klopper K., Yamini P., Bendix-Waltes R., Dork T., and Karstens J.H. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol 69 (2003) 155-160
30. Cesaretti J.A., Stock R.G., Lehrer S., et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 61 (2005) 196-202
31. Meyer A., John E., Dork T., Sohn C., Karstens J.H., and Bremer M. Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy. Radiother Oncol 72 (2004) 319-323
32. Anscher M.S., Kong F.M., and Jirtle R.L. The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer 19 (1998) 109-120
33. Andreassen C.N. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles?. Acta Oncol 44 (2005) 801-815
34. Andreassen C.N., Alsner J., Overgaard J., et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 75 (2005) 18-21
35. Andreassen C.N., Alsner J., Overgaard M., and Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 69 (2003) 127-135
36. Angele S., Romestaing P., Moullan N., et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 63 (2003) 8717-8725
37. Quarmby S., Fakhoury H., Levine E., et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 79 (2003) 137-143
38. Baumann M., Holscher T., and Begg A.C. Towards genetic prediction of radiation responses: ESTRO's GENEPI project. Radiother Oncol 69 (2003) 121-125
39. Abraham J, Earl HM, Poole CJ, et al. PG-SNPs: a pharmaco-genetic study of chemotherapy in early breast cancer trials. NCRI Cancer Conference; Poster 52:29.